A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of BGM0504 Injection in Healthy Participants and Participants With Impaired Renal Function
The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
• √ Age 18-65 years on the date of signing informed consent (inclusive);
‣ Body mass index (BMI) within the range of 19.0-30.0 kg/m2 (inclusive);.
⁃ Stable renal function, assessed by two eGFR during screening (apart at least 3 days);
⁃ Diagnosed as stable, chronic renal disease for at least 3 months.
⁃ Renal function, assessed by estimated glomerular filtration rate at screening (eGFR):
• Normal renal function: 90-129 mL/min (inclusive);
∙ Mild impairment: 60-89 mL/min (inclusive);
∙ Moderate impairment: 30-59 mL/min (inclusive);
∙ Severe impairment: 15-29 mL/min (inclusive);